Molecule News and Research

RSS

Pre-clinical data of GM1485 to be presented by GliaMed

GliaMed, Inc., a development stage biopharmaceutical company, today announced that Dr. David Weinstein, chief scientific officer and company founder, will present pre-clinical data demonstrating acceleration of wound healing through the in vivo induction and recruitment of stem cells at the Stem Cells USA & Regenerative Medicine Congress in Washington, D.C.

18 Nov 2009

Press conference highlights emerging treatments in pancreatic cancer

As part of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Thompson will moderate a press conference on emerging treatments in pancreatic cancer on Tuesday, Nov. 17, 2009, in Room 202 of the Hynes Convention Center in Boston, Mass., from 1:00 p.m. to 2:00 p.m. ET.

18 Nov 2009

Helicos Genetic Analysis System to be installed at the Leiden Genome Technology Center

Helicos BioSciences Corporation, today announced the sale of a Helicos® Genetic Analysis System to a collaborative Dutch research group led by the Leiden University Medical Center (LUMC), further including the medical centers of Amsterdam (AMC) Groningen (UMCG) and Rotterdam (Erasmus MC) and funded by a grant from NWO, the Netherlands Organization of Scientific Research.

17 Nov 2009

YM BioSciences presents preclinical results of its small molecule VDA at the AACR-NCI-EORTC conference

YM BioSciences Inc., a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, announced that preclinical results for CYT997 were presented today in a poster by Cytopia Limited at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference in Boston, Massachusetts.

17 Nov 2009

Anacor Pharmaceuticals commences patient dosing in AN3365 Phase I clinical study

Anacor Pharmaceuticals today announced that it has dosed the first patient in a Phase I clinical study for AN3365, a novel boron-based, small-molecule drug candidate in development for the treatment of hospital infections caused by Gram-negative bacteria. The study will evaluate the safety, tolerability and pharmacokinetics of AN3365 in healthy volunteers.

17 Nov 2009

Th22 cell to control inflammation in body to help fight off infection discovered

A new type of immune cell that can be out of control in certain chronic inflammatory diseases, worsening the symptoms of conditions like psoriasis and asthma, is described for the first time in the Journal of Clinical Investigation.

17 Nov 2009

LEAD Therapeutics discovers orally available PARP inhibitor

LEAD Therapeutics, a privately held drug discovery company, today announced the discovery of a novel, orally available, PARP inhibitor with potent anti-tumor activity both as single-agent treatment and in combination with chemotherapy drugs.

17 Nov 2009

NIH awards $3 million grant to ASU professors for research on rapid DNA sequencing technology

Arizona State University has been awarded nearly $3 million in federal stimulus funds from the National Institutes of Health. ASU professors Stuart Lindsay and Paul Westerhoff will lead a pair of two-year, innovative projects designed to tackle challenges in the fields of rapid DNA sequencing and the potential health risks of nanotechnology.

17 Nov 2009

Additional data from Aegerion Pharmaceuticals' ongoing lomitapide Phase III trial

Aegerion Pharmaceuticals, Inc., a biopharmaceutical company focused on the treatment of cardiovascular and metabolic disease, today announced additional data from its ongoing Phase III trial involving its lead cholesterol management compound, lomitapide (AEGR-733), which is a microsomal triglyceride transfer protein (MTP) inhibitor small molecule drug.

16 Nov 2009

4SC raises funds for further development of its current product pipeline

4SC AG, a drug discovery and development company, today announced the successful completion of a capital increase, after the Management Board, with the approval of the Supervisory Board, passed a resolution to authorise an increase of share capital on 23 October, 2009.

16 Nov 2009

Fate Therapeutics announces the completion of $30 million Series B financing

Fate Therapeutics, Inc. announced today that it has completed a $30 million Series B financing led by OVP Venture Partners. Joining OVP Venture Partners in the financing is a syndicate of corporate investors, including Astellas Venture Management, Genzyme Ventures and a third undisclosed corporate investor.

16 Nov 2009

NRC helps Olympus to design and commercialize CARS microscope

The National Research Council Canada (NRC) recently helped Olympus, a world leader in advanced optical microscopy and medical imaging, to design and commercialize a CARS (Coherent Anti-stokes Raman Scattering) microscope.

From Evident Corporation - Life Sciences 16 Nov 2009

Research team identifies five new gene regions that raise the risk of childhood-onset IBD

In the largest, most comprehensive genetic analysis of childhood-onset inflammatory bowel disease (IBD), an international research team has identified five new gene regions, including one involved in a biological pathway that helps drive the painful inflammation of the digestive tract that characterizes the disease.

16 Nov 2009

Phase I clinical study for ETC-1002 commenced

Esperion Therapeutics, a privately held biotechnology company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced that the company has initiated a Phase I clinical study for ETC-1002, the company's novel small molecule compound designed to beneficially regulate the levels of plasma lipids and lipoproteins.

16 Nov 2009

Ore Pharmaceutical Holdings reports financial results and provides operational updates for third quarter 2009

Ore Pharmaceutical Holdings Inc. today reported financial results and provided an operational update for the third quarter ended September 30, 2009.

13 Nov 2009

CSHL solves the structure of the zinc-bound ATD domain of the NMDA receptor NR2B subunit

A team of scientists at Cold Spring Harbor Laboratory (CSHL) reports on Thursday their success in solving the molecular structure of a key portion of a cellular receptor implicated in Alzheimer's, Parkinson's, and other serious illnesses.

13 Nov 2009

Lipid that accumulates in brain cells drives cell death, says research

The lipid that accumulates in brain cells of individuals with an inherited enzyme disorder also drives the cell death that is a hallmark of the disease, according to new research led by St. Jude Children's Research Hospital investigators.

13 Nov 2009

Mithridion reports progress with its potential oral small-molecule drugs for AD and schizophrenia

Mithridion, Inc., a biopharmaceutical company focusing on developing drugs for serious Central Nervous System (CNS) disorders, announced today progress with its pipeline of potential oral small-molecule drugs for Alzheimer's disease (AD) and schizophrenia.

13 Nov 2009

Stapled Peptides directly inhibit the Notch transcription factor complex

Aileron Therapeutics, a biopharmaceutical company leading the development of a new class of drugs called Stapled Peptides, announced today that its collaborators, James E. Bradner, MD of the Dana-Farber Cancer Institute and the Broad Institute of Harvard and MIT, and Gregory L. Verdine, PhD, Professor of Chemistry at Harvard University, published research in Nature entitled, “Direct Inhibition of the Notch Transcription Factor Complex.”

12 Nov 2009

Stapled Peptides can inhibit key intracellular biological targets, says new research

Aileron Therapeutics, a biopharmaceutical company leading the development of a new class of drugs called Stapled Peptides, announced today that its collaborators, James E. Bradner, MD of the Dana-Farber Cancer Institute and the Broad Institute of Harvard and MIT, and Gregory L. Verdine, PhD, Professor of Chemistry at Harvard University, published research in Nature entitled, "Direct Inhibition of the Notch Transcription Factor Complex." Results presented in the paper showed that Stapled Peptides can potently and directly inhibit the transcription factor Notch, an oncogene implicated in cancer cell proliferation and survival.

12 Nov 2009

Molecule News and Research

Pre-clinical data of GM1485 to be presented by GliaMed

Press conference highlights emerging treatments in pancreatic cancer

Helicos Genetic Analysis System to be installed at the Leiden Genome Technology Center

YM BioSciences presents preclinical results of its small molecule VDA at the AACR-NCI-EORTC conference

Anacor Pharmaceuticals commences patient dosing in AN3365 Phase I clinical study

Th22 cell to control inflammation in body to help fight off infection discovered

LEAD Therapeutics discovers orally available PARP inhibitor

NIH awards $3 million grant to ASU professors for research on rapid DNA sequencing technology

Additional data from Aegerion Pharmaceuticals' ongoing lomitapide Phase III trial

4SC raises funds for further development of its current product pipeline

Fate Therapeutics announces the completion of $30 million Series B financing

NRC helps Olympus to design and commercialize CARS microscope

Research team identifies five new gene regions that raise the risk of childhood-onset IBD

Phase I clinical study for ETC-1002 commenced

Ore Pharmaceutical Holdings reports financial results and provides operational updates for third quarter 2009

CSHL solves the structure of the zinc-bound ATD domain of the NMDA receptor NR2B subunit

Lipid that accumulates in brain cells drives cell death, says research

Mithridion reports progress with its potential oral small-molecule drugs for AD and schizophrenia

Stapled Peptides directly inhibit the Notch transcription factor complex

Stapled Peptides can inhibit key intracellular biological targets, says new research

Industry Focus eBook - Cell biology (5th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News